Katan is not a traditional strategic consulting firm. Because we work with a carefully selected group of clients each year, our role with our client companies goes far beyond a simple evaluation or the completion of a single transaction.
MERGERS & ACQUISITIONS
Katan specializes is assisting companies with less than US $50 million in revenue, with particular emphasis on the therapeutics, diagnostics, device, and lab supply/reagents segments of the Life Sciences sector.
Partnering has been the life blood of the Life Sciences industry, both for large and small companies. Katan maintains relationships with numerous global pharmaceutical and biotechnology companies to assist clients in partnering transactions.
Katan has worked with, on behalf of and as a direct investor in many companies since inception. Often Katan Principals take a managerial role in such projects and is proud to have a track record of success in several global pharmaceutical and biotechnology companies.
At Katan we create strategies that permit technology based companies to achieve
their full commercial value. Katan is not a traditional strategic consulting firm. Because we work with a carefully selected group of clients each year, our role with our client companies goes far beyond a simple evaluation or the completion of a single transaction. We invest the time needed and effort required to know management, to understand the business, and most importantly, to shape the implications of the strategies which we help to implement. Overall we seek to build long-term relationships through our value contribution.
Katan's operational and capitalization strategies for Life Sciences companies have been
delivered on a successful basis for over a decade.
Since our founding, we have been successful in:
Working with the CEOs of numerous companies on the development of strategies that have improved overall operations and increased long-term shareholder value.
Providing advice to several government entities across the globe in the creation and implementation of numerous strategies to support the development and commercialization of biotechnology research, as part of their respective goals to establish themselves as a leader in the new biotechnology economy.
Formulating paths to liquidity for entrepreneurs, management teams, and investors.
We realize that our effectiveness is limited by the credibility we maintain with our extensive relationship base. As such, we pride ourselves on developing long-term client partnerships that allow us to leverage our excellent global relationships.
At Katan we work carefully with a selected group of clients each year, we take the time to understand the transactional requirements and operational needs that are fundamental to the creation of long-term shareholder value.
Our evaluation process is simple. We make a determination of the following criteria:
Do we believe that the people involved can get the job done?
Does the product/technology/company have a sustainable competitive advantage?
Do we share similar expectations of value and outcomes?
Can we add value to the company/process given our involvement?
Upon obtaining a mandate, we meet face-to-face to understand and evaluate the management team, technology, and financial position of a company. We then determine what is required to increase value, grow, and commercialize the technology. Based upon this evaluation and subsequent due diligence, we design and develop a fully integrated strategy, from both an operational and capitalization perspective, to permit technology based companies to achieve their full commercial value. Next, we take a role, in some contexts an operational role, assisting our clients in the implementation and execution of these strategies. Our end goal is to create enhanced value for our clients, something we have been fortunate to achieve in numerous assignments.
500 S. Sepulveda Blvd. Suite 212
Manhattan Beach, CA 90266
T: 310 374 0808 F: 310 374 0803
E: Seth Yakatan
Shimon Ben Shetach Street 11 Elad 4082611 Israel
T, F: +972 (3) 909 1813
E: Prof. Alf Fischbein